Travecta showcases its novel blood-brain barrier transport platform in New York, USA
Travecta Therapeutics is one of eight companies that will present at SPRIM’s quarterly Ventures Day meeting in New York on April 24. The event will provide insights into the latest innovations and trends in biotech and digital health.
Travecta will showcase its novel blood-brain barrier transport platform and what it could mean for treating disorders of the central nervous system.
SPRIM Ventures and Tikehau Capital (TKO.FP) are hosting the Ventures Day event on behalf of their venture capital fund TKS 1. TKS 1 provides early-stage capital to innovative companies offering solutions that move science forward in the health sector. Travecta was seeded by TKS 1 in 2017.
Tikehau Capital is an alternative asset management and investment group with €15.9 billion of assets under management (as of 30 September 2018) and shareholders’ equity of €2.3 billion (as of 30 June 2018). The group invests in various asset classes (private debt, real estate, private equity and liquid strategies), including through its asset management subsidiary Tikehau IM, on behalf of institutional and private investors. Controlled by its managers, alongside leading institutional partners, Tikehau Capital employs 260 staff (as of 30 September 2018) in its Paris, London, Brussels, Madrid, Milan, New York, Seoul and Singapore offices.
SPRIM Ventures is the venture arm of SPRIM, a life-science consulting agency for the full lifecycle of a product. Multi-nationals, startups, institutions and governments around the world turn to SPRIM for expertise in developing relevant, fresh and meaningful health innovations. From traditional categories like nutrition, cosmetics, personal care, prescription and medical devices, to the new health frontier of digital-connected devices and algorithm-based diagnostics, SPRIM brings together game-changing science and winning commercial results.